Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model
Kamira Maharaj, John J. Powers, Melanie Mediavilla-Varela, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 20

Showing 20 citing articles:

Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies
Ailin Zhao, Hui Zhou, Jinrong Yang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 60
A Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective Inhibitors
Anna Fontana, Ilaria Cursaro, Gabriele Carullo, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 17, pp. 10014-10014
Open Access | Times Cited: 29
Targeting Indoleamine Dioxygenase and Tryptophan Dioxygenase in Cancer Immunotherapy: Clinical Progress and Challenges
Xuerun Peng, Zhipeng Zhao, Liwen Liu, et al.
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 2639-2657
Open Access | Times Cited: 28
HDAC6 inhibitor ACY-1215 enhances STAT1 acetylation to block PD-L1 for colorectal cancer immunotherapy
Yuqing Wen, Shuyu Ye, Zhengshuo Li, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 1
Open Access | Times Cited: 7
Reducing PD-L1 Expression by Degraders and Downregulators as a Novel Strategy to Target the PD-1/PD-L1 Pathway
Zhijie Wang, L. Yuan, Xiaotong Liao, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 8, pp. 6027-6043
Closed Access | Times Cited: 7
Novel Agents in Chronic Lymphocytic Leukemia: New Combination Therapies and Strategies to Overcome Resistance
Moritz Fürstenau, Barbara Eichhorst
Cancers (2021) Vol. 13, Iss. 6, pp. 1336-1336
Open Access | Times Cited: 36
Recent development of selective inhibitors targeting the HDAC6 as anti-cancer drugs: Structure, function and design
Jie Peng, Fei Xie, Pengxia Qin, et al.
Bioorganic Chemistry (2023) Vol. 138, pp. 106622-106622
Open Access | Times Cited: 13
Progress of research on PD-1/PD-L1 in leukemia
Huizhen Cao, Tianyu Wu, Xue Zhou, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 12
Current treatment strategies targeting histone deacetylase inhibitors in acute lymphocytic leukemia: a systematic review
Yingjun Zhang, Ge Zhang, Yuefang Wang, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 4
Discovery of Novel Hydrazide-Based HDAC3 Inhibitors as Epigenetic Immunomodulators for Cancer Immunotherapy
Zhiqiang Sun, Jinmei Cheng, Chenglong Xu, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Epigenetic Landscapes Drive CAR-T Cell Kinetics and Fate Decisions: Bridging Persistence and Resistance
Kecheng Wang, Kaixin Ou, Yu Zeng, et al.
Critical Reviews in Oncology/Hematology (2025), pp. 104729-104729
Closed Access
Histone deacetylases (HDACs) as the promising immunotherapeutic targets for hematologic cancer treatment
Feifei Yang, Ting Hu, Jianquan Liu, et al.
European Journal of Medicinal Chemistry (2022) Vol. 245, pp. 114920-114920
Closed Access | Times Cited: 16
BET inhibition reforms the immune microenvironment and alleviates T cell dysfunction in chronic lymphocytic leukemia
Audrey L. Smith, Sydney A. Skupa, Alexandria P. Eiken, et al.
JCI Insight (2024) Vol. 9, Iss. 10
Open Access | Times Cited: 3
Immunomodulatory properties of HDAC6 inhibitors in cancer diseases: New chances for sophisticated drug design and treatment optimization
Bernhard Biersack, Bianca Nitzsche, Michael Höpfner
Seminars in Cell and Developmental Biology (2022) Vol. 154, pp. 286-294
Closed Access | Times Cited: 14
Targeting HDAC6 to Overcome Autophagy-Promoted Anti-Cancer Drug Resistance
Hyein Jo, Kyeonghee Shim, Dooil Jeoung
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 17, pp. 9592-9592
Open Access | Times Cited: 13
PD-L1 Expression in Neoplastic and Immune Cells of Thymic Epithelial Tumors: Correlations with Disease Characteristics and HDAC Expression
Ioanna Ε. Stergiou, Kostas Palamaris, Georgia Levidou, et al.
Biomedicines (2024) Vol. 12, Iss. 4, pp. 772-772
Open Access | Times Cited: 2
A novel potent class I HDAC inhibitor reverses the STAT4/p66Shc apoptotic defect in B cells from chronic lymphocytic leukemia patients
Sara Rossi, Vanessa Tatangelo, Maria Dichiara, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 174, pp. 116537-116537
Open Access | Times Cited: 2
Selective HDAC6 Inhibition Has the Potential for Anti-Cancer Effect in Renal Cell Carcinoma
Tsutomu Anraku, Masaki Murata, Hiroo Kuroki, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 7, pp. 704-704
Open Access | Times Cited: 2
Acetylation in Tumor Immune Evasion Regulation
Jun Lu, Xiang He, Lijuan Zhang, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 11
Migration and Adhesion of B-Lymphocytes to Specific Microenvironments in Mantle Cell Lymphoma: Interplay between Signaling Pathways and the Epigenetic Landscape
Laia Sadeghi, Anthony P. H. Wright
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 12, pp. 6247-6247
Open Access | Times Cited: 7
Biological, prognostic, and therapeutic impact of the epigenome in CLL
Alba Maiqués-Díaz, José I. Martín‐Subero
Seminars in Hematology (2023) Vol. 61, Iss. 3, pp. 172-180
Closed Access | Times Cited: 2
Page 1

Scroll to top